Evidence map›Paper›PMID 31384610›Full record

ArticleProstate international2019

Is it safe to continue antithrombotic agents before prostate biopsy?

Kuniaki Tanabe, Tomotaka Hattori, Hirohito Kobayashi, Kyoko Koike, Yasuhiro Maki, Takashi Arai, Toshiaki Otsuka, Yasutomo Suzuki, Yukihiro Kondo, Naoki Kawamura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Kuniaki TanabeDepartment of Urology, Nippon Medical School, Tokyo, Japan.
Tomotaka HattoriDepartment of Urology, Ebina General Hospital, Kanagawa, Japan.
Hirohito KobayashiDepartment of Urology, Ebina General Hospital, Kanagawa, Japan.
Kyoko KoikeDepartment of Urology, Ebina General Hospital, Kanagawa, Japan.
Yasuhiro MakiDepartment of Urology, Ebina General Hospital, Kanagawa, Japan.
Takashi AraiDepartment of Urology Kitakyushu General Hospital, Fukuoka, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Yasutomo SuzukiDepartment of Urology, Nippon Medical School Chiba Hokusou Hospital, Chiba, Japan.
Yukihiro KondoDepartment of Urology, Nippon Medical School, Tokyo, Japan.
Naoki KawamuraDepartment of Urology, Ebina General Hospital, Kanagawa, Japan.
Nippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether antithrombotic agents should be stopped before prostate biopsy is unsettled. We investigated the impact of antithrombotic agents on bleeding complications after prostate biopsy. MATERIALS AND

methodsAmong the patients who underwent transrectal ultrasound-guided prostate biopsy from June 2006 to December 2013 at Ebina General Hospital, Kanagawa, Japan, 1817 cases were retrospectively assessed. Patients were divided into two groups: those not taking antithrombotic agents (control group) and those taking them (experimental group). The frequency and severity of bleeding complications after the procedure were compared. The severity of bleeding events was graded using the Common Terminology Criteria for Advanced Events vol. 4.0.

resultsHemorrhagic complications were classified into grades 1 to 3. Patients with complications of Grade 2 and above needed treatment. As for the Grade 1 event, there were no differences between two groups. The frequency of more than Grade 2 bleeding events was 1.7% and 3.5% in the control and experimental group, respectively; the odds ratio was 2.18 (

conclusionsThe present study showed that continuation of antithrombotic agents increased the frequency of hemorrhagic complications requiring intervention. It suggests that attention should be paid to the patients taking antithrombotic agents before prostate biopsy.

Indexed as

AA, antithrombotic agentAC, anticoagulant agentAnticoagulantsAP, antiplatelet agentASA, acetylsalicylic acidBiopsyHemorrhageMAP, major antiplatelet agentOR, odds ratioPlatelet aggregation inhibitorsProstatePSA, prostate-specific agentRR, relative riskSD, standard deviationTE, thromboembolismTPV, total prostate volumeTRUS, transrectal ultrasound

Identifiers

PMID31384610
PMCPMC6664272
OpenAlexW2868987063

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.